Niagen Bioscience News and Activities
Presence
Niagen Bioscience develops and sells healthy aging products and ingredients. Its main offerings include nutritional supplements, functional ingredients, and scientific support for consumers, healthcare professionals, and business partners.
Niagen Bioscience products and services overview:
- Dietary supplements
- Healthy aging products
- Nutritional ingredients
- Consumer wellness products
- Research services
Revenue: ~$100 million
Employees: 120
Headquarters: Los Angeles, United States (USA)
Niagen Bioscience is one of the...
Niagen Bioscience is a company listed under the stock ticker NAGE (US).
Executives
View the org chart displaying its 13 main executives
Most searched biographies at Niagen Bioscience
- Robert Fried, Chief Executive Officer and Director
- Kristin Patrick, Director
- Wendy Yu, Non-Executive Director
Create your alert
to follow the executive moves at Niagen Bioscience.
Pharmaceuticals
Niagen Bioscience has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Niagen Bioscience
- ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
- ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
- ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
- ChromaDex Corporation Reports Third Quarter 2024 Financial Results
- ChromaDex Corporation Reports Third Quarter 2024 Financial Results
- ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- ChromaDex to Participate in the 17th Annual LD Micro Main Event
- ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- Niagen+ | Pharmaceutical-grade Niagen (NR) IV and Injectable
- Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
- View more press releases Close
Social media about Niagen Bioscience
- Niagen Bioscience on Wikipedia, Google News & Yahoo Finance
- Niagen Bioscience on LinkedIn, X (Twitter) & YouTube
